Amplyx Pharmaceuticals

Amplyx Pharmaceuticals mainly focuses on developing novel broad-spectrum antifungal drugs, with the vision of overcoming the significant lack of existing antifungal treatment options.Fosmanogepix, developed by Amplyx Pharmaceuticals for treating lethal fungal infections, is a unique antifungal therapy targeting Gwt1, a conserved fungal enzyme. By inhibiting Gwt1, fosmanogepix can suppress the proliferation of important fungal pathogens such as Candida and Aspergillus. Since fosmanogepix does not inhibit PIGW, the human homolog gene closest to Gwt1, it can inhibit the growth of fungal pathogens without harming the patient's healthy cells.